Treatment of Staphylococcus aureus Pneumonia in Outpatient Adults with Chronic Comorbidities
Community-acquired pneumonia caused by Staphylococcus aureus in outpatient adults with underlying chronic conditions represents a distinct clinical scenario with specific evidence-based treatment recommendations. The presence of comorbidities directly informs antibiotic selection in this setting.
Clinical Scenario
Adult patient with community-acquired pneumonia managed in the outpatient setting, with one or more of the following comorbidities:
Chronic heart disease
Chronic lung disease
Chronic liver disease
Chronic renal disease
Diabetes mellitus
Alcoholism
Malignancy
Asplenia
Treatment Goals
The clinical endpoint is achievement of stability: resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), restored ability to eat, and normal mentation. Therapy continues until these criteria are met and for no less than a total of 5 days. Most patients reach stability within the first 48 to 72 hours.
Approach — partial summary
Management involves either combination antibiotic therapy — pairing a beta-lactam with a complementary agent — or monotherapy with a respiratory fluoroquinolone. The specific agents, the choice between combination and monotherapy, and the full sequencing are covered in the structured protocol.
References
DOI: 10.1164/rccm.201908-1581ST
- For outpatient adults with comorbidities such as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia we recommend (in no particular order of preference) (Table 3):
- amoxicillin/clavulanate 500 mg/125 mg three times daily, or amoxicillin/clavulanate 875 mg/125 mg twice daily, or 2,000 mg/125 mg twice daily, or a cephalosporin (cefpodoxime 200 mg twice daily or cefuroxime 500 mg twice daily); AND
- macrolide (azithromycin 500 mg on first day then 250 mg daily, clarithromycin [500 mg twice daily or extended release 1,000 mg once daily]) (strong recommendation, moderate quality of evidence for combination therapy), or doxycycline 100 mg twice daily (conditional recommendation, low quality of evidence for combination therapy); OR
- respiratory fluoroquinolone (levofloxacin 750 mg daily, moxifloxacin 400 mg daily, or gemifloxacin 320 mg daily) (strong recommendation, moderate quality of evidence).
- We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).
- As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.
View source ↗